1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,147 | 0,162 | 10:13 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.01. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 06.01. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | 1 | HKEx | ||
| 23.12.24 | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | 1 | HKEx | ||
| VIVA BIOTECH Aktie jetzt für 0€ handeln | |||||
| 11.12.24 | Viva Biotech Establishes New Branch in Boston | 2 | Contract Pharma | ||
| 11.12.24 | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | 1 | HKEx | ||
| 11.12.24 | Viva Biotech Officially Establishes Boston Branch, Marking Another Milestone in Global Expansion | 293 | PR Newswire | HONG KONG, Dec. 11, 2024 /PRNewswire/ -- Recently, Viva Biotech Holdings Group ("Viva Biotech") announced the official establishment of its new branch in Boston, USA. As a global leader in... ► Artikel lesen | |
| 02.12.24 | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 14.11.24 | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 06.11.24 | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 30.10.24 | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 15.10.24 | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 08.10.24 | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | 1 | HKEx | ||
| 27.09.24 | VIVA BIOTECH (01873): VOLUNTARY ANNOUNCEMENT COMPLETION OF JOINT-STOCK CONVERSION OF VIVA SHANGHAI AND CHANGE OF ROLES OF CO-CHIEF FINANCIAL OFFICER | - | HKEx | ||
| 26.09.24 | VIVA BIOTECH (01873): INTERIM REPORT 2024 | - | HKEx | ||
| 25.09.24 | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 13.09.24 | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | 1 | HKEx | ||
| 13.09.24 | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS (REVISED) | 1 | HKEx | ||
| 05.09.24 | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 29.08.24 | Viva Biotech Holdings: Viva Biotech Announces Its 2024 Interim Results: Significant Improvement in Net Profit Growth and Ongoing Optimization of Emerging Technology Platforms | 101 | PR Newswire | Results Highlights for Interim Results ended 30 June 2024
Revenue reached RMB981.8 million Gross profit amounted to RMB339.1 million Net profit grew by 956.0 YoY to RMB144.2 million Adjusted non-IFRS... ► Artikel lesen | |
| 28.03.24 | Viva Biotech Holdings: Viva Biotech (1873.HK) Announces 2023 Annual Results: Successful Implementation of Light-asset Strategy, Achieving Solid Growth and Promising Future | 159 | PR Newswire | HONG KONG, March 28, 2024 /PRNewswire/ --
Highlights of the Annual Results as of December 31, 2023:
Revenue reached RMB2,155.6 million
Gross profit amounted to RMB738.5 million
Adjusted non-IFRS... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 3,282 | -3,58 % | Valneva-Aktie: Höhenflug erstmal zu Ende? | Die Valneva-Aktie hat in diesem Jahr eine fulminante Kursexplosion erlebt. Doch am heutigen Dienstag verliert sie kräftig auf aktuell 3,76 €. Ist der Höhenflug jetzt erstmal zu Ende? Analyst optimistisch... ► Artikel lesen | |
| NOVONESIS | 58,88 | +1,10 % | Novonesis (Novozymes A/S): 12M 2024: Novonesis delivers strong full-year results and expects continued growth in 2025 | Novonesis delivers 8% organic sales growth with an adjusted EBITDA margin of 36.1% in 2024. For 2025, Novonesis presents an outlook of 5-8% organic sales growth with an adjusted EBITDA margin of 37-38%.... ► Artikel lesen | |
| GENMAB | 219,70 | +2,95 % | Genmab A/S - admittance to trading and official listing of new shares due to employee warrant exercise | The share capital of Genmab A/S has been increased. The admittance to trading and official listing will take effect as per 28 February 2025 in the ISIN below.
ISIN:
DK0010272202
Name:
Genmab
Volume... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,292 | +0,73 % | Arbutus Biopharma Corporation: Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna | BASEL, Switzerland and VANCOUVER, British Columbia and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and... ► Artikel lesen | |
| BEIGENE LTD ADR | 232,00 | -0,85 % | BeiGene, Ltd.: BeiGene gibt Finanzergebnisse für das vierte Quartal und das Gesamtjahr 2024 sowie Geschäftsaktualisierungen bekannt | Gesamtumsatz weltweit von 1,1 Milliarden US-Dollar und 3,8 Milliarden US-Dollar für das vierte Quartal und das Gesamtjahr, was einem Anstieg von 78 bzw. 55 entspricht; verringerter GAAP-Betriebsverlust... ► Artikel lesen | |
| MOLECULIN BIOTECH | 2,450 | -100,00 % | Moleculin stock target cut to $8 at H.C. Wainwright | ||
| SINO BIOPHARM | 0,392 | +2,78 % | SINO BIOPHARM (01177): NOTIFICATION OF BOARD MEETING | ||
| VERICEL | 49,000 | +3,81 % | Vericel Corporation: Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results | Full-Year Total Revenue Growth of 20% to $237.2 Million, with MACI Revenue Growth of 20% and Burn Care Revenue Growth of 22% Full-Year Adjusted EBITDA Growth of 58% to $53.4 Million Record Fourth... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 0,445 | +7,23 % | Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones | - Solnerstotug (SNS-101) dose expansion arm anticipated to be fully enrolled by end of Q1 2025 - - Clinical data update expected in Q2 2025 - BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 2,950 | -100,00 % | BioXcel Therapeutics Announces $14 Million Registered Direct Offering | ||
| MUSTGROW BIOLOGICS | 0,756 | -3,57 % | MustGrow Biologics Corp.: MustGrow Signs Exclusive Distribution Agreement with Adjuvants Plus Inc. for Biological Product Line | Saskatoon, Saskatchewan--(Newsfile Corp. - February 11, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), a leading provider of biological and regenerative... ► Artikel lesen | |
| ZAI LAB LTD ADR | 30,800 | +1,32 % | Zai Lab Limited Q4 Loss Declines | BEIJING (dpa-AFX) - Zai Lab Limited (ZLAB) revealed Loss for fourth quarter of -$81.68 millionThe company's earnings totaled -$81.68 million, or -$0.08 per share. This compares with -$95.43... ► Artikel lesen | |
| REGENXBIO | 6,300 | +11,50 % | Regenxbio Aktie: Wolf im Schafspelz? | Der Biotechnologiekonzern Regenxbio verzeichnet aktuell eine herausfordernde Marktphase. Die Aktie des Unternehmens, das sich auf Gentherapie-Produktkandidaten spezialisiert hat, notiert derzeit bei... ► Artikel lesen | |
| AKEBIA | 1,717 | -0,35 % | Akebia Therapeutics, Inc.: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease... ► Artikel lesen | |
| CSTONE PHARMACEUTICALS | 0,422 | +3,94 % | CStone Pharmaceuticals: CStone Announces Publication of GEMSTONE-303 Study Results for Sugemalimab (Cejemly) in JAMA | Sugemalimab is the world's first anti-PD-L1 monoclonal antibody approved for the treatment of gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. The... ► Artikel lesen |
Das Unternehmen VIVA BIOTECH HOLDINGS kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,005 (-3,21 %) liegt der Kurs bei 0,151 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIVA BIOTECH HOLDINGS finden Sie auf Wallstreet Online.
